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Abstract
AIM: To investigate the mechanism and significance of
NF-kB activation regulated by hepatitis B virus X protein
(HBx) in hepatitis B virus (HBV)-associated hepatocellular
carcinoma (HCC).
METHODS: The expression levels of HBx, p65, IkB-a and
ubiquitin were detected by immunohistochemistry in HCC
tissue microarrays (TMA) respectively, and IkB-a was detected
by Western blot in HCC and corresponding liver tissues.
RESULTS: The percentage of informative TMA samples was
98.8% in 186 cases with a total of 367 samples. Compared
with corresponding liver tissues (60.0%), the HBx expression
was obviously decreased in HBV-associated HCC (47.9%,
u=2.24, P<0.05). On the contrary, the expressions of p65
(20.6% vs 45.3%, u=4.85, P<0.01) and ubiquitin (8.9% vs
59.0%, u=9.68, P<0.01) were notably elevated in HCC. In
addition, IkB-a had a tendency to go up. Importantly, positive
relativity was observed between HBx and p65 (c2=10.26,
P<0.01), p65 and IkB-a (c2=16.86, P<0.01), IkB-a and
ubiquitin (c2=8.90, P<0.01) in HCC, respectively.
CONCLUSION: Both active and non-active forms of NF-kB
are increased in HBV-associated HCC. Variant HBx is the
major cause of the enhancement of NF-kB activity. The
activation always proceeds in nucleus and the proteasome
complexes play an important role in the activation.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is a malignant tumor with a
poor prognosis. Hepatitis B virus (HBV) has been shown to
be linked epidemiologically to the HCC development and about
eighty percent of the tumors in China are induced by HBV. As
a unique non-structure protein, hepatitis B virus X protein
(HBx) performs a variety of biological functions, such as gene
transactivation[1], interaction with p53[2], interference with host
DNA repair[3], repression of physiological proteolysis[4],
modulation of cell proliferation and apoptosis[5,6], induction of
malignant cell migration[7,8]. These functions may play an
important role in the initiation and development of HCC
associated with HBV infection. NF-kB, a crucial transcriptor,
takes part in almost all aspects of cell regulation, including
immune cell activation, stress response, proliferation,
apoptosis, differentiation and oncogenic transformation.
Currently, more attentions have been paid to the carcinogenesis
of HBx transactiving NF-kB[9]. However, the active state of
NF-kB in HCC has been seldom studied. As a new high-
throughput technology introduced in 1999, tissue microarray
(TMA) is worthy of popularization. In our study, the expression
levels of HBx, p65, IkB-a and ubiquitin were detected by
immunohistochemistry on TMA respectively, as well as IkB-a
was detected by Western blot, in order to investigate the
mechanism and significance of HBx activating NF-kB.
MATERIALS AND METHODS
Tissue samples
Paraffin specimens were prepared from operatively-resected
HCC and non-HCC counterparts between 1997 and 2000,
including 171 cases of serum HBV-positive HCC, 10 cases of
serum HBV-negative HCC and their corresponding liver
tissues, 5 cases of normal control liver tissues (Table 1). In
addition, 24 couples of fresh HCC and its corresponding liver
tissues were collected between March and October in 2001,
stored at -80  until experiment.
Tissue microarray construction
All formalin-fixed and paraffin-embedded HCC tissues used
in this study were sectioned and stained with hematoxylin-
eosin (H&E). The H&E-stained sections were carefully
diagnosed, and the representative regions of the tumor and its
corresponding liver tissue for microarray were defined as well.
HCC TMA was constructed according to the procedure
described by Kononen et al[10]. Briefly, core tissue specimens,
0.6 mm in diameter, were taken from selected regions of
individual donor blocks and precisely arrayed into recipient
paraffin blocks (45 mm×22 mm) using a tissue-arraying
instrument (Beecher Instruments, Silver Spring, MD, USA).
After construction, the recipient paraffin block was incubated
at 37  for one hour and the surface of the block was smoothed.
Five-micrometer consecutive sections of this TMA block were
cut with a microtome. The presence and morphology of tumor
and liver tissues on arrayed samples were identified by H&E
stained sections.
Immunohistochemistry
TMA section was deparaffinized through xylene and dehydrated
with graded alcohol. Endogenous peroxidase was then blocked
with 0.3% H202 diluted in methanol for 30 min at room
temperature. Antigen retrieval was performed by treating the
slide in citrate buffer in a microwave for 10 min. The slide
was incubated in a moist chamber with HBx mouse monoclonal
antibody (1:100; Chemicon, USA), p65 mouse monoclonal
antibody (Santa Cruz, USA), IkB-a rabbit polyclonal antibody
(Santa Cruz, USA) and ubiquitin rabbit polyclonal antibody
(Neomarkers, USA) at 4  overnight respectively. After a
brief wash in PBS, the slide was treated with goat anti-mouse
antibody and goat anti-rabbit antibody (EnVisionTM +Kits,
DAKO, Denmark), respectively, for 45 min at 37 . After a
brief wash in PBS, the slide was developed in 0.05% freshly
prepared diaminobenzedine solution (DAB, Sigma, St. Louis,
MO) for 8 min, and then counterstained with hematoxylin.
More than 5% cells stained were identified as a positive result.
Western blot
Western blot was carried out based on the protocol of molecular
clone[11]. Briefly, frozen tissues were lysed in a single eradicator
buffer (150 mmol/L NaCl, 50 mmol/L pH 8.0 Tris-HCl, 0.02%
natriumazid, 1 ug/ml aprotinin, 100 ug/ml PMSF, 1% Triton
X-100) and quantified by BCA method. The samples were
boiled, loaded, separated on 12% SDS gel electrophoresis,
transferred to nitrocellulose membrane, and reacted with IkB-
a rabbit polyclonal antibody (1:1 000, Santa Cruz, USA). At
last, the membrane was exposed several minutes after ECL
substrate incubation.
Statistical analysis
HBx, p65, IkB-a, ubiquitin expression differences between
HBV-associated HCC and corresponding liver tissues were
analyzed statistically using u test. The relativity between HBx,
IkB-a, p65, ubiquitin was analyzed statistically using c2 test
or adjusted c2 test.
RESULTS
Tissue microarray
In this study, two HCC TMA blocks were constructed which
contained a total of 181 cases with 367 samples. One thousand
four hundred fifty-one informative samples were totally
detected by immunohistochemistry on arrays and the observed
ratio was up to 98.8% (1 451/1 468 samples). HE-stained
sections showed that the morphology of tissues and cells could
be seen clearly. The HCC array HE-stained sections and several
types of the tumor are shown in Figure 1.
Figure 1  Overview of HCC TMA. A: TMA overview of H&E-
staining section, B: HCC morphology on TMA stained by H&E.
Table 1  Clinicopathologic information of patients used in TMA
     HBV         Sex    Age                 Diameter            Grade   Cirrhosis
Group
Total  Positive      Negative Man Female         mean±SD (year)     mean±SD (cm)  II  III  IV Yes No
HCC   181     171 10  158     23 49.3±10.6    7.2±3.5 28 141 12 166  15
Normal       5         0   5      2       3 42.4±9.6    9.3±5.8     0    5
Table 2  Expressions of HBx, p65, IkB-a and ubiquitin in HCC and corresponding liver tissues
             HBx             p65           IkB-a       Ubiquitin
Group
            Total    Positive     %         Total     Positive        %         Total      Positive      %         Total      Positive       %
HCC 169   81 47.9           170 77 45.3           170 124 72.9           166 98 59.0
Control 170 102 60.0           170 35 20.6           171 116 67.0           168 15   8.9
Statistics            u=2.24a           u=4.85b             u=1.19            u=9.68b
aP<0.05, bP<0.01.
Table 3  Relativity analysis between HBx, IkB-a, p65 and ubiquitin in HCC and corresponding liver tissues
HBx P65 Ubiquitin
Negative Positive Negative Positive Negative Positive
HBx Negative    58(52)   30(16)    39(57)   46(8)
Positive    33(83)   47(19)    28(95)   52(7)
Statistics         c2=10.26b(0.60)          c2=2.02(1.44)
IkB-a Negative    29(21)   17(34)    36(46)     9(9)    26(50)   17(4)
Positive    59(47)   63(68)    56(89)   68(26)    42(103)   80(11)
Statistics            c2=2.28(0.11)          c2=16.86b(1.02)          c2=8.90b(0.04)
bP<0.01, vs Corresponding liver tissue.
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Figure 2  Expressions and locations of HBx, p65, IkB-a and
ubiquitin in HCC detected by immunohistochemistry,
EnVision ×200. A: HBx expression in cytoplasm, B: p65
immunostaining in cytoplasm and nuclei, C: IkB-a distribu-
tion in cytoplasm and nuclei, D: ubiquitin location in nuclei.
Expression differences of four proteins in HCC and
corresponding liver tissues
The expression of HBx was restricted exclusively to
cytoplasmic location in both HCC and liver tissues. The
positive immunostainings of p65 and IkB-a were seen only in
cytoplasm of liver tissues, but in both cytoplasm and nuclei of
HCC. The positive signal of ubiquitin was distributed
predominantly in cytoplasm of liver tissues and in nuclei of
HCC (Figure 2).
       In serum HBV-positive cases, the HBx expressions in HCC
(81/169, 47.9%) were significantly decreased as compared with
the corresponding liver tissues (102/170, 60.0%, P<0.05). On
the contrary, the expressions of p65 and ubiquitin were notably
elevated in HCC (45.3%, 59.0% respectively) as compared
with corresponding liver tissues (20.6%, 8.9% respectively,
P<0.01). The positive rate of immunostaining reaction of IkB-
a in HCC and corresponding liver tissues was 72.9% and 67%
respectively. The difference was not significant, though the
staining in HCC was more intense (Table 2).
     In serum HBV-negative cases, the expressions of HBx,
p65, IkB-a, ubiquitin in HCC were detected in 2/10 cases, 5/9
cases, 7/9 cases and 5/10 cases respectively. In corresponding
liver tissues, their expressions were detected in 2/10 cases,
2/9 cases, 7/9 cases and 2/10 cases respectively.
     In five normal liver tissues, all expressions of HBx, p65
and ubiquitin were negative, whereas, IkB-a was demonstrated
to be weakly positive.
Western blot of IkB-a
Compared with corresponding liver tissues, elevated levels of
IkB-a were detected in 10 HCC cases, decreased in 1 case. In
the other 13 couples of HCC and corresponding liver tissues,
no obvious difference of expression was detected (Figure 3).
Figure 3  IkB-a expression levels detected by Western blot. IkB-
a levels were elevated in 3 cases of HCC compared with their
corresponding liver tissues.
Relativity analysis between HBx, IkB-k, p65 and ubiquitin
c2 test showed that no relativity existed between HBx, IkB-a,
p65 and ubiquitin in corresponding liver tissues, but a positive
relativity was observed between HBx and p65, p65 and IkB-a,
IkB-a and ubiquitin in HCC (Table 3).
DISCUSSION
TMA is a new technology first introduced in 1999. It contains
hundreds or even thousands of small tissue samples arranged
into a grid for rapid, cost efficient and high-throughput analysis.
TMA has been used widely in gene or protein expression
analysis, antibody screening, tissue specificity detection of
proteins, phenotype versus genotype analysis, RNA or DNA
in situ-hybridization[10,12,13]. Based on TMA, we studied the
expressions of HBx, NF-kB, IkB-a, ubiquitin and their
interrelationship in HCC.
      The result of HBx expression detection in HBV-associated
HCC showed that HBx expression was reduced in cancer
tissue as compared with the corresponding liver tissue. The
result might be ascribed to the existing form of HBV in tumor
tissue. Many researches indicated that integration was the
major form of HBV in HCC, so the viral copies were far less
than that in non-tumor tissues where free virus prevails[14].
The expression of HBx in samples with serum HBV-negative
implicated quite a few patients were once infected with HBV.
Moreover, the cytoplasmic location of HBx was consistent
with the previous reports[15].
    NF-kB plays a vital role in almost all aspects of cell
regulation such as immune cell activation, proliferation,
apoptosis, stress response, differentiation and oncogenic
transformation. Activated NF-kB can mediate the expression
of a large (more than 150) and diverse set of inflammatory
and immune response mediators. It has been considered as a
central regulator of cellular responses and played a pivotal
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role both at the stage of initiation and perpetuation of chronic
inflammation[16-19]. NF-kB is sequestered in the cytosol of
unstimulated cells via non-covalent interactions with a class
of inhibitor proteins, called IkBs. Signals that induce NF-kB
activity cause the phosphorylation of IkBs, their dissociation
and subsequent ubiquitination and degradation in 26S
proteasome complex, allowing NF-kB proteins to enter the
nucleus and induce gene expression by binding kB site in DNA.
As one of the NF-kB activation products, IkB-a could induce
NF-kB export from the nucleus by reuniting NF-kB and
terminating associated gene activation. The negative feedback
loop could keep NF-kB sensitivity to signals by returning
rapidly to baseline activity[20-22].
      Because p65 is one of the most common members in NF-
kB family, and IkB-a is the most important inhibitor, detection
of p65 and IkB-a expression can reflect the state of NF-kB
metabolism. In our test, low expression rate of p65 and weakly
positive expression of IkB-a represented the nonactive state of
NF-kB in non-cancerous tissues, but the activation enhancement
of NF-kB in HCC was in accord with the previous reports[23,24].
The expression of IkB-a in HCC and its corresponding liver
tissue has not been reported yet. In our study, no statistical
difference was found in positive rates between HCC and its
corresponding liver tissue, the discrimination of immunostaining
intensity was scented. Furthermore, Western blot validated the
concentration augmentation of IkB-a in HCC, while in the
meantime, molecular weight alteration was not observed. The
results illustrated that IkB-a regulation gave priority to quantity
change in HCC. The location of p65 and IkB-a represented
the activation or non-activation form of NF-kB. Quite a few
cytoplasm locations of p65 and IkB-a observed in our test
accounted for the non-activated NF-kB increase in HCC, which
contradicted with cytoplasm decrease of p65 and IkB-a
observed in vivo system[25]. We ascribed the contradiction of
NF-kB metabolism to the persistence in HCC and the transience
in vivo system. The lasting activation of NF-kB can automatically
regulate the production of IkB-a and possibly even p65 or
p50. A great deal of non-activated NF-kB repertory is in favor
of lasting activation of NF-kB.
      IkB-a proteolysis is by the ubiquitin-proteasome pathway,
but the exact locality is still not clear. Birbach et al expatiated
IkB-a shuttle mechanism between cytoplasm and nucleus[26].
It is recognized now that besides IkB-a, up-stream kinases
such as NIK and MAPKK can shuttle between cytoplasm and
nucleus. The present study is the first to show the distribution
and expression of ubiquitin in HCC. The results of nuclear
location of ubiquitin and its relativity with IkB-a indicated
the proteolysis of IkB-a was processed in tumor cell nuclei.
Of course, another likelihood was that transcription of ubiquitin
would be promoted after NF-kB activation[27]. There is no
relativity between ubiquitin and HBx, so whether the
proteolysis of HBx passes through non-ubiquitin pathway or
not remains to be determined.
      Positive relativity between HBx and p65 in HCC indicated
that HBx existed in tumor tissues was one cause of inducing
NF-kB activation. It has been found in some studies that HBx
mutation was common in HCC compared with corresponding
liver tissues[28]. Frequent types of HBx mutation were COOH-
terminal truncation and hotspot mutations in certain amino
acids[29-31]. COOH-terminally truncated HBx is encoded by
truncated X gene, which usually derives from HBV integrated
into host genome. Base mutation and frame-shift are the other
causes. Usually, it was considered that HBx activated NF-kB
relied on its transactivation domains, and COOH-terminal
transactivation domain was important to its transactivation
function[32,33]. In our study, NF-kB activation was elevated in
HCC with a low HBx expression compared with corresponding
liver tissues. Therefore, the results implied that HBx might
activate NF-kB by other unknown mechanisms but not its
transactivation ability. One likeness was that C-terminally
truncated HBx lost its ability to suppress proteasome complex
and facilitated IkB-a degradation and NF-kB activation[4]. The
high percentage of ubiquitin expressions in HCC (59.0%) from
our results in part supports the opinion. The detailed mechanism
of NF-kB activation in HBV-associated hepatocellular
carcinoma remains to be further studied.
     In conclusion, NF-kB activation induced by HBx could
not only facilitate infected cell survival and HBV escape from
immune clearance, but also promote liver cell malignant
transformation and tumor cell advantageous growth[34]. Variant
HBx plays an important role in potentiating NF-kB activation.
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